We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Creo Medical Group Plc | LSE:CREO | London | Ordinary Share | GB00BZ1BLL44 | ORD GBP0.001 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.15 | 3.28% | 36.25 | 36.00 | 36.50 | 36.50 | 35.25 | 35.25 | 590,751 | 14:57:46 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Surgical,med Instr,apparatus | 27.17M | -26.94M | -0.0746 | -4.86 | 130.95M |
From Apr 2019 to Apr 2024
TIDMCREO
RNS Number : 5141E
Creo Medical Group PLC
12 February 2018
Creo Medical Group plc
Exercise of Options 12 February 2018
Creo Medical Group plc ("Creo") confirms that it has issued, conditional on admission, 276,320 new ordinary shares of GBP0.001 each in the capital of Creo (the "New Shares"), pursuant to an exercise of share options.
Application has been made to the London Stock Exchange for admission of the New Shares to trading on AIM and dealings are expected to commence on 16 February 2018 ("Admission"). Following Admission, Creo will have a total of 81,103,065 ordinary shares of GBP0.001 each in issue. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in Creo.
Contacts
Hot Features
Premium
Creo Medical: Cenkos: FTI Consulting:
Richard Rees Camilla Hume/Mark Brett Pollard
+44 (0)129 160 6005 Connelly (NOMAD) / Mo Noonan
Richard.Rees@creomedical.com Michael Johnson +44 (0)203 727
/ Russell Kerr 1000
(Sales) creo@fticonsulting.com
+44 (0)207 397
8900
About Creo Medical
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.
For more information about Creo Medical please see our website, www.creomedical.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEMMGGZLLGGRZM
(END) Dow Jones Newswires
February 12, 2018 02:00 ET (07:00 GMT)
1 Year Creo Medical Chart |
1 Month Creo Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
